Department for Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Section Medical Physiology, Department of Neuroscience, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
J Neurochem. 2019 Oct;151(1):11-27. doi: 10.1111/jnc.14841. Epub 2019 Sep 9.
Adenosine receptor subtypes, first described 40 years ago, are known to regulate diverse biological functions and have a role in various conditions, such as cerebral and cardiac ischemia, immune and inflammatory disorders and cancer. In the brain, they limit potentially dangerous over excitation, but also regulate mechanisms essential in sleep and psychiatric disorders. In this review, we discuss the role of adenosine receptors in mood and anxiety disorders. Activation of A receptors is associated with increased depression-like symptoms, while increased A receptors signaling elicits rapid antidepressant effects. Indeed, several lines of evidence demonstrate that the therapeutic effects of different non-pharmacological treatments of depression, like sleep deprivation and electroconvulsive therapy are mediated by A receptor up-regulation or activation. In addition, A receptors may also play a role in the antidepressant effects of transcranial direct current stimulation and deep brain stimulation. As a potential downstream mechanism, which facilitates the antidepressant effects of A receptors, we propose a crosstalk between adenosinergic and glutamatergic systems mediated via synaptic plasticity protein Homer1a and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Moreover, adenosine receptors are also involved in the control of circadian rhythms, sleep homeostasis and some neuro-immunological mechanisms, all of them implicated in mood regulation. Antagonists of adenosine receptors such as caffeine have general anxiogenic effects. In particular, A receptors appear to have an important role in the pathophysiology of anxiety disorders. Taken together, the results discussed here indicate that the adenosinergic system is involved in both the etiology and the treatment of mood and anxiety disorders.
腺嘌呤受体亚型于 40 年前首次被描述,已知其调节多种生物学功能,并在多种情况下发挥作用,如脑和心脏缺血、免疫和炎症性疾病以及癌症。在大脑中,它们限制潜在的危险过度兴奋,但也调节睡眠和精神障碍等基本机制。在这篇综述中,我们讨论了腺嘌呤受体在情绪和焦虑障碍中的作用。A 受体的激活与抑郁样症状的增加有关,而增加的 A 受体信号转导则引发快速的抗抑郁作用。事实上,有几条证据表明,不同非药物治疗抑郁症的治疗效果,如睡眠剥夺和电惊厥疗法,是通过 A 受体的上调或激活介导的。此外,A 受体也可能在经颅直流电刺激和深部脑刺激的抗抑郁作用中发挥作用。作为促进 A 受体抗抑郁作用的潜在下游机制,我们提出了通过突触可塑性蛋白 Homer1a 和α-氨基-3-羟基-5-甲基-4-异恶唑丙酸受体介导的腺嘌呤能和谷氨酸能系统之间的串扰。此外,腺嘌呤受体还参与昼夜节律的控制、睡眠稳态和一些神经免疫机制的调节,所有这些都与情绪调节有关。腺嘌呤受体拮抗剂,如咖啡因,具有普遍的焦虑作用。特别是,A 受体似乎在焦虑障碍的病理生理学中具有重要作用。综上所述,这里讨论的结果表明,腺嘌呤能系统参与了情绪和焦虑障碍的病因和治疗。